Literature DB >> 10024593

Chlamydia pneumoniae infection in human monocytes.

S Airenne1, H M Surcel, H Alakärppä, K Laitinen, J Paavonen, P Saikku, A Laurila.   

Abstract

Chlamydia pneumoniae infection has been associated with cardiovascular diseases in seroepidemiological studies and by demonstration of the pathogen in atherosclerotic lesions. It has the capacity to infect several cell types, including monocyte-derived macrophages, which play an essential role in the development of atherosclerosis. However, the persistence of C. pneumoniae in mononuclear cells is poorly understood. To study the morphology and biological characteristics of the infection, human peripheral blood monocytes were infected with C. pneumoniae. Freshly isolated monocytes resisted the development of infectious progeny, and confocal and transmission electron microscopy showed that the morphology of the inclusions and chlamydial particles was abnormal. Addition of tryptophan or antibodies against gamma interferon did not diminish the inhibition of C. pneumoniae, suggesting that other factors are involved in the chlamydiostatic activity of the monocytes. Chlamydial mRNA was expressed at least 3 days after infection, however, and a capability for infected monocytes to induce a positive lymphocyte proliferative response was detected for up to 7 days, indicating that C. pneumoniae remains metabolically active in the monocytes in vitro. These results are in accordance with the hypothesis that C. pneumoniae may participate in the maintenance of local immunological response and inflammation via infected monocytes and thus enhance atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024593      PMCID: PMC96479     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.

Authors:  D L Hahn; R W Dodge; R Golubjatnikov
Journal:  JAMA       Date:  1991-07-10       Impact factor: 56.272

2.  Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages.

Authors:  J M Carlin; E C Borden; G I Byrne
Journal:  J Interferon Res       Date:  1989-06

Review 3.  A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.

Authors:  J T Grayston; L A Campbell; C C Kuo; C H Mordhorst; P Saikku; D H Thom; S P Wang
Journal:  J Infect Dis       Date:  1990-04       Impact factor: 5.226

4.  Intracellular persistence of chlamydial major outer-membrane protein, lipopolysaccharide and ribosomal RNA after non-productive infection of human monocytes with Chlamydia trachomatis serovar K.

Authors:  E Schmitz; E Nettelnbreker; H Zeidler; M Hammer; E Manor; J Wollenhaupt
Journal:  J Med Microbiol       Date:  1993-04       Impact factor: 2.472

5.  An epidemic of infections due to Chlamydia pneumoniae in military conscripts.

Authors:  M R Ekman; J T Grayston; R Visakorpi; M Kleemola; C C Kuo; P Saikku
Journal:  Clin Infect Dis       Date:  1993-09       Impact factor: 9.079

Review 6.  Effect of clinically relevant culture conditions on antimicrobial susceptibility of Chlamydia trachomatis.

Authors:  P B Wyrick; C H Davis; J E Raulston; S T Knight; J Choong
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

7.  Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene.

Authors:  C A Gaydos; T C Quinn; J J Eiden
Journal:  J Clin Microbiol       Date:  1992-04       Impact factor: 5.948

Review 8.  The pathogenesis of atherosclerosis: a perspective for the 1990s.

Authors:  R Ross
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

9.  Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures.

Authors:  J M Carlin; J B Weller
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

10.  In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae.

Authors:  K L Godzik; E R O'Brien; S K Wang; C C Kuo
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

View more
  31 in total

1.  Cell-mediated immune response during primary Chlamydia pneumoniae infection.

Authors:  S Halme; J Latvala; R Karttunen; I Palatsi; P Saikku; H M Surcel
Journal:  Infect Immun       Date:  2000-12       Impact factor: 3.441

2.  Chlamydia pneumoniae secretion of a protease-like activity factor for degrading host cell transcription factors required for [correction of factors is required for] major histocompatibility complex antigen expression.

Authors:  Peiyi Fan; Feng Dong; Yanqing Huang; Guangming Zhong
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

Review 3.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

4.  Depletion of resident Chlamydia pneumoniae through leukoreduction by filtration of blood for transfusion.

Authors:  Hideaki Ikejima; Herman Friedman; German F Leparc; Yoshimasa Yamamoto
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

5.  Chlamydia pneumoniae enhances cytokine-stimulated human monocyte matrix metalloproteinases through a prostaglandin E2-dependent mechanism.

Authors:  Min P Kim; Charlotte A Gaydos; Billie Jo Wood; Justin P Hardick; Yahong Zhang; Larry M Wahl
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

6.  Influence of different delivery modes on the clinical characteristics of Chlamydia trachomatis pneumonia.

Authors:  Jiejing Xu; Lili Yu; Baidi Fu; Deyu Zhao; Feng Liu
Journal:  Eur J Pediatr       Date:  2018-05-31       Impact factor: 3.183

7.  Analysis of Chlamydia pneumoniae infection in mononuclear cells by reverse transcription-PCR targeted to chlamydial gene transcripts.

Authors:  Laura Mannonen; Eveliina Markkula; Mirja Puolakkainen
Journal:  Med Microbiol Immunol       Date:  2011-01-30       Impact factor: 3.402

8.  Opsonophagocytosis of Chlamydia pneumoniae by Human Monocytes and Neutrophils.

Authors:  Mads Lausen; Mathilde Selmar Pedersen; Nareen Sherzad Kader Rahman; Liv Therese Holm-Nielsen; Faduma Yahya Mohamed Farah; Gunna Christiansen; Svend Birkelund
Journal:  Infect Immun       Date:  2020-06-22       Impact factor: 3.441

9.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Chlamydia pneumoniae growth inhibition in cells by the steroid receptor antagonist RU486 (mifepristone).

Authors:  Hiroyuki Yamaguchi; Shigeru Kamiya; Tomonori Uruma; Takako Osaki; Haruhiko Taguchi; Tomoko Hanawa; Minoru Fukuda; Hayato Kawakami; Hajime Goto; Herman Friedman; Yoshimasa Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  2008-03-17       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.